The ophthalmologists joining the board are David Boyer, MD, of Retina-Vitreous Associates Medical Group in the Los Angeles area, and Lawrence J. Singerman, MD, of Retina Associates of Cleveland.
The board is comprised of retinal ophthalmology experts who are brought on to assist in advancing Ohr Pharmaceutical’s squalamine eye drop program into clinical efficacy trials.
“We are pleased to be working with thought leaders in the retina community of the caliber of Drs. Boyer and Singerman,” said Irach B. Taraporewala, PhD, CEO of Ohr Pharmaceutical, in the release. “Their addition to our ophthalmic scientific advisory board, together with their past experience in the clinical advancement of numerous FDA approved retinal therapeutics, including Eylea and Lucentis, will immensely help the company move the squalamine eye drop program forward into its first clinical trial, which is expected to begin in the third quarter of 2012.
Ohr Pharmaceutical is headquartered in New York.
Related Articles on Ophthalmologists:
Ophthalmologist on the Move: Dr. Rand Diab Rejoins IN’s Hammond Clinic
Ophthalmologist on the Move: Dr. Keith Knuth Joins IN’s Glick Eye Institute
